Vitamin a derivative patch could reverse oral precancer

NCT ID NCT07149220

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a sticky patch that releases fenretinide, a vitamin A derivative, directly onto precancerous spots inside the mouth. The goal is to see if the patch can shrink these lesions, reduce their severity under the microscope, and lower genetic changes linked to oral cancer. The study involves healthy volunteers and people with confirmed oral precancer, who apply the patch twice daily for six weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

fenretinide mucoadhesive system

What this could lead to

If effective, this patch could offer a non-surgical way to reverse precancerous mouth lesions and lower the risk of oral cancer.

What could go wrong

This is a small early-phase trial, so results may not confirm effectiveness. The patch may cause irritation or fail to shrink lesions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ORAL DYSPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

intraepithelial neoplasia oral mucosa leukoplakia lip and oral cavity carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio State University College of Dentistry

    Columbus, Ohio, 43210, United States